Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
July 25, 2020
Theacrine, a purine alkaloid from kucha, protects against Parkinson's disease through SIRT3 activation
Wen-Jun Duan, Lei Liang, Ming-Hai Pan, et al.
Aging Cell
|
August 25, 2023
Membrane phospholipid peroxidation promotes loss of dopaminergic neurons in psychological stress-induced Parkinson's disease susceptibility
Xiao-Min Lin, Ming-Hai Pan, Jie Sun, et al.
The Journal of Biological Chemistry
|
August 17, 2021
Structure, dynamics, and regulation of TRF1-TIN2-mediated trans- and cis-interactions on telomeric DNA
Hai Pan, Parminder Kaur, Ryan Barnes, et al.
Nature Communications
|
September 27, 2024
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Dalong Zhu, Weimin Wang, Guoyu Tong, et al.
Molecular Metabolism
|
June 26, 2023
Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Wanjun Guo, Zheng Xu, Haixia Zou, et al.
Journal of Translational Medicine
|
October 30, 2025
CircSipa1l1 modulates melanoma cell differentiation by activating the IGF2BP1-ARHGDIB axis and ERK signaling pathway
Bo-Han Li, Ling Liu, Dan Shi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 13, 2020
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial
Yanhang Gao, Fei Kong, Guangming Li, et al.
The Lancet. Diabetes & Endocrinology
|
June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Linong Ji, Leili Gao, Haibo Xue, et al.
The Journal of Clinical Investigation
|
May 15, 2023
Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
Jie Sun, Xiao-Min Lin, Dan-Hua Lu, et al.
The Lancet. Diabetes & Endocrinology
|
August 25, 2025
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
Yang He, Nianrong Mi, Zhifeng Cheng, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|
July 25, 2020
Theacrine, a purine alkaloid from kucha, protects against Parkinson's disease through SIRT3 activation
Wen-Jun Duan, Lei Liang, Ming-Hai Pan, et al.
Aging Cell
|
August 25, 2023
Membrane phospholipid peroxidation promotes loss of dopaminergic neurons in psychological stress-induced Parkinson's disease susceptibility
Xiao-Min Lin, Ming-Hai Pan, Jie Sun, et al.
The Journal of Biological Chemistry
|
August 17, 2021
Structure, dynamics, and regulation of TRF1-TIN2-mediated trans- and cis-interactions on telomeric DNA
Hai Pan, Parminder Kaur, Ryan Barnes, et al.
Nature Communications
|
September 27, 2024
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Dalong Zhu, Weimin Wang, Guoyu Tong, et al.
Molecular Metabolism
|
June 26, 2023
Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Wanjun Guo, Zheng Xu, Haixia Zou, et al.
Journal of Translational Medicine
|
October 30, 2025
CircSipa1l1 modulates melanoma cell differentiation by activating the IGF2BP1-ARHGDIB axis and ERK signaling pathway
Bo-Han Li, Ling Liu, Dan Shi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 13, 2020
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial
Yanhang Gao, Fei Kong, Guangming Li, et al.
The Lancet. Diabetes & Endocrinology
|
June 24, 2025
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Linong Ji, Leili Gao, Haibo Xue, et al.
The Journal of Clinical Investigation
|
May 15, 2023
Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
Jie Sun, Xiao-Min Lin, Dan-Hua Lu, et al.
The Lancet. Diabetes & Endocrinology
|
August 25, 2025
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
Yang He, Nianrong Mi, Zhifeng Cheng, et al.
Page
of 12